-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
For nanobiotix's critical Phase III trial for the treatment of head and neck cancer, its regional start-up work is proceeding as planned, and Liantuo completes the first patient recruitment in Asia
The collaboration continues to strengthen Liantao's industry leadership in Asia, while Nanobiotix will continue to focus on planned market launches and global recruitment
On September 7, 2022, nanobiotix, a biotechnology company in the late stages of clinical development, and Liantuo Biologics, a biotechnology company focused on bringing innovative drugs to patients in key markets in China and Asia, jointly announced that Nanobiotix's GLOBAL PHASE III clinical trial of NANOY-312 begins randomized treatment of the first patient in Asia, which aims to evaluate the use of NBTXR3 for the treatment of locally advanced head and neck squamous cell carcinoma that is not suitable for cisplatin ( LA-HNSCC) elderly patients
"NBTXR3 has shown potential to improve efficacy in a variety of solid tumor indications, including results
NANORAY-312 is an international, dual-arm, randomized, investigator-selected Phase III registered trial to study the efficacy and safety
The NANORAY-312 trial is based on Study #102 of Nanobiotix, a Phase I trial designed to evaluate the safety and early efficacy signs
Liantuo Bio has exclusive development and commercialization rights for NBTXR3 in the Greater China, South Korea, Singapore and Thailand markets
About NBTXR3
NBTXR3 is a novel, potentially pioneering antineoplastic drug consisting of functionalized hafnium dioxide nanoparticles administered by a disposable intratumboma injection and activated
About NANOBIOTIX
Nanobiotix is a late-stage clinical development biotechnology company that works with industry peers committed to benefiting humanity to deliver unprecedented therapeutic outcomes
About Liantuo Biologics
LianBio is a multinational biotechnology company whose mission is to bring disruptive medicines
